Human immunodeficiency virus type 1 Group-specific antigen (Gag) and Envelope glycoprotein (Env) peptide epitopes (HIV-1 Gag and Env peptide epitopes)

HIV-1 Gag and Env peptide epitopes are specific amino acid sequences derived from the major structural and surface proteins of the Human Immunodeficiency Virus type 1. The Gag polyprotein (Pr55Gag) is essential for the assembly, budding, and maturation of viral particles, while the Env glycoprotein (gp160) mediates viral attachment to CD4 receptors and subsequent membrane fusion (UniProt: P04591, P04578). These epitopes are critical targets in the design of vaccines and immunotherapies, as they are recognized by T-cell receptors and neutralizing antibodies (Los Alamos HIV Database). Therapeutic strategies involve using these peptides to stimulate the host immune system to identify and destroy infected cells or to prevent the virus from entering healthy cells. However, the high genetic diversity and rapid mutation rate of HIV-1 often lead to "viral escape," where the virus alters these epitopes to evade immune detection (PubMed: 28410382). Additionally, the Env protein is heavily glycosylated, which acts as a "glycan shield" to protect conserved epitopes from antibody neutralization (PubMed: 30104379).

Other names

HIV-1 Gag/Env epitopesGag-Env peptidesHIV-1 structural protein epitopesPr55Gag and gp160 epitopesHIV-1 Gag and Env antigens

Vaccine-mediated induction of HIV-specific CD8+ cytotoxic T-lymphocytes and CD4+ helper T-cells, as well as the production of broadly neutralizing antibodies (bNAbs) that bind to Env epitopes to prevent viral entry (NIH: NIAID HIV Vaccine Research). Monoclonal antibodies directly bind to Env epitopes (gp120 or gp41) to block viral attachment or fusion (PubMed: 30224648).